Top Tweets for #TOFACITINIB

about 17 hours ago

💊 CAN TOFACITINIB HELP REDUCE GULCOCORTICOID EXPOSURE? The real-world DRESS study of 61 patients found that adding #tofacitinib to systemic glucocorticoids was associated with shorter treatment duration, lower cumulative #glucocorticoid exposure, and faster near-complete rash resolution 👉 https://t.co/qFaF1ZHFmn #Dermatology #Tofacitinib #JAKInhibitors #ClinicalResearch #MedTwitter #SkinHealth #Glucocorticoids

Pharmexy Global @Pharmexy_exp

1 day ago

#Tofacitinib #Tofacent5 #RheumatoidArthritis #PsoriaticArthritis #UlcerativeColitis #JAKInhibitor #Pharmaceuticals #Pharma #Healthcare #PharmexyGlobal

Pharmexy Global @Pharmexy_exp

1 day ago

Tofacent 5 mg - Tofacitinib 5 mg Tofacent 5 is a JAK inhibitor used in the treatment of certain inflammatory and autoimmune conditions, including: • Rheumatoid Arthritis (RA) • Psoriatic Arthritis (PsA) • Ulcerative Colitis (UC) Pack Size: 60 Tablets #Tofacitinib #Tofacent5

Pharmexy_exp's tweet photo. Tofacent 5 mg - Tofacitinib 5 mg
Tofacent 5 is a JAK inhibitor used in the treatment of certain inflammatory and autoimmune conditions,
including:

• Rheumatoid Arthritis (RA)
• Psoriatic Arthritis (PsA)
• Ulcerative Colitis (UC)

Pack Size: 60 Tablets
#Tofacitinib #Tofacent5 https://t.co/lGwqvcWxw3

JPGN Reports @JPGNReports

about 1 month ago

Mahajan et al 🔥 Infantile-onset #IBD + refractory?? Combo therapy wins?! #Tofacitinib + #ustekinumab → 100% remission (clinical + endoscopic) in a tiny but tough cohort AND no AEs 👀 Game changer or just early hype? 🤔 🔗 https://t.co/BDQ7kMP3f2 #PedsGI #VEOIBD #JAKi

$JPGNReports's tweet photo. Mahajan et al 🔥 Infantile-onset #IBD + refractory?? Combo therapy wins?! #Tofacitinib + #ustekinumab → 100% remission (clinical + endoscopic) in a tiny but tough cohort AND no AEs 👀 Game changer or just early hype? 🤔 🔗 https://t.co/BDQ7kMP3f2 #PedsGI #VEOIBD #JAKi https://t.co/A4uVyWH6HA$

208

Annie Kleynerman Roels @AnnieKleyRoels

about 1 month ago

✅ No significant differences in flow-mediated dilation magnitude 🟢 #Infliximab maintained physiologic NO-mediated dilation 🔴 #Tofacitinib shifted toward H₂O₂-mediated dilation ❓#Upadacitinib impaired NO-mediated dilation without compensatory H₂O₂ signaling ➡️ Anti-TNF and selective vs. non-selective JAK inhibition produced distinct endothelial phenotypes, highlighting potential differences in #cardiovascular effects. ➡️One step closer to precision medicine for patients with #IBD? https://t.co/qLFrhaRVpA

201

Alberto Giraldo @alb_giraldo

3 months ago

A recent systematic literature review evaluated the efficacy and safety of Janus kinase inhibitors (JAKi — primarily #tofacitinib, #baricitinib, and #upadacitinib) in #Behçet's syndrome (BS), including a case of gastrointestinal involvement treated with upadacitinib. 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗣𝗼𝗽𝘂𝗹𝗮𝘁𝗶𝗼𝗻 ◦ 92 patients (48 men, mean age 38.5 years). ◦ Heavily pre-treated: Nearly all had failed at least one conventional immunosuppressive; 57.6% were refractory to at least one TNF inhibitor. ◦ JAKi were mostly used in combination with conventional immunosuppressants and/or glucocorticoids (90.6% of cases). 𝗠𝗮𝗶𝗻 𝗶𝗻𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗝𝗔𝗞𝗶 ◦ Gastrointestinal involvement: 50% (most common). ◦ Vascular involvement: 23.9%. ◦ Uveitis/ocular involvement: 20.6%. ◦ Mucocutaneous and/or articular involvement: 5.6%. 𝗘𝗳𝗳𝗶𝗰𝗮𝗰𝘆 (𝗿𝗲𝗺𝗶𝘀𝘀𝗶𝗼𝗻 𝗿𝗮𝘁𝗲𝘀) ◦ Overall remission: 85.9%. ◦ Gastrointestinal: 82.6%. ◦ Vascular: 90.9%. ◦ Ocular (eye): 84.2%. 𝗦𝗮𝗳𝗲𝘁𝘆 ◦ Serious adverse events occurred in only 5.4% of patients. ◦ No thrombotic events were reported. 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝘁��𝗶𝘀 𝘀𝘁𝘂𝗱𝘆 ◦ TNF inhibitors remain the only agents proven effective across all BS manifestations. ◦ JAKi achieved ~86% remission in a difficult-to-treat population. However, these promising results are based on observational data and case reports. ◦ Further high-quality trials are required to properly compare efficacy and safety against existing therapies. *Sulu B, Esatoglu SN, Kurtulus-Erozkan G, Hatemi I, Celik AF, Hatemi G. Efficacy and safety of JAK inhibitors in Behçet syndrome: Systematic literature review. Semin Arthritis Rheum. Published online June 19, 2026. 🔗https://t.co/s3PUQauPYM

$alb_giraldo's tweet photo. A recent systematic literature review evaluated the efficacy and safety of Janus kinase inhibitors (JAKi — primarily #tofacitinib, #baricitinib, and #upadacitinib) in #Behçet's syndrome (BS), including a case of gastrointestinal involvement treated with upadacitinib. 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗣𝗼𝗽𝘂𝗹𝗮𝘁𝗶𝗼𝗻 ◦ 92 patients (48 men, mean age 38.5 years). ◦ Heavily pre-treated: Nearly all had failed at least one conventional immunosuppressive; 57.6% were refractory to at least one TNF inhibitor. ◦ JAKi were mostly used in combination with conventional immunosuppressants and/or glucocorticoids (90.6% of cases). 𝗠𝗮𝗶𝗻 𝗶𝗻𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗝𝗔𝗞𝗶 ◦ Gastrointestinal involvement: 50% (most common). ◦ Vascular involvement: 23.9%. ◦ Uveitis/ocular involvement: 20.6%. ◦ Mucocutaneous and/or articular involvement: 5.6%. 𝗘𝗳𝗳𝗶𝗰𝗮𝗰𝘆 (𝗿𝗲𝗺𝗶𝘀𝘀𝗶𝗼𝗻 𝗿𝗮𝘁𝗲𝘀) ◦ Overall remission: 85.9%. ◦ Gastrointestinal: 82.6%. ◦ Vascular: 90.9%. ◦ Ocular (eye): 84.2%. 𝗦𝗮𝗳𝗲𝘁𝘆 ◦ Serious adverse events occurred in only 5.4% of patients. ◦ No thrombotic events were reported. 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝘁��𝗶𝘀 𝘀𝘁𝘂𝗱𝘆 ◦ TNF inhibitors remain the only agents proven effective across all BS manifestations. ◦ JAKi achieved ~86% remission in a difficult-to-treat population. However, these promising results are based on observational data and case reports. ◦ Further high-quality trials are required to properly compare efficacy and safety against existing therapies. *Sulu B, Esatoglu SN, Kurtulus-Erozkan G, Hatemi I, Celik AF, Hatemi G. Efficacy and safety of JAK inhibitors in Behçet syndrome: Systematic literature review. Semin Arthritis Rheum. Published online June 19, 2026. 🔗https://t.co/s3PUQauPYM$

275

Scleroderma Forum

@ScleroForum

3 months ago

👋 Huang et al. found that combination therapy including #Tofacitinib achieved greater skin improvement than MTX alone in patients with #SSc from a nationwide Chinese multicentre registry cohort. Learn more here: https://t.co/kDDDJPDF7C #SclerodermaForum

ScleroForum's tweet photo. 👋 Huang et al. found that combination therapy including #Tofacitinib achieved greater skin improvement than MTX alone in patients with #SSc from a nationwide Chinese multicentre registry cohort.

Learn more here: https://t.co/kDDDJPDF7C

#SclerodermaForum https://t.co/za0zZ8JJGo

Nelly ZIADE 🍀 @Nellziade

3 months ago

⚡ Can #tofacitinib induce remission in early #axSpA? FASTLANE (Phase 4 RCT, n=107) YES! ASDAS inactive disease 26.4% vs 7.4% placebo at Wk16 #OP0241 #EULAR2026 @RheumNow

Nellziade's tweet photo. ⚡ Can #tofacitinib induce remission in early #axSpA?

FASTLANE (Phase 4 RCT, n=107)
YES! ASDAS inactive disease 26.4% vs 7.4% placebo at Wk16

#OP0241 #EULAR2026 @RheumNow https://t.co/uLicY6njtY

116

Scleroderma Forum

@ScleroForum

3 months ago

🔬 Real-world data from Huang et al. showed #Tofacitinib led to greater longitudinal improvement in physician global assessment and skin sclerosis in patients with #SSc. View the full slide deck here:🔗https://t.co/t6XbHiqrLC #SclerodermaForum

ScleroForum's tweet photo. 🔬 Real-world data from Huang et al. showed #Tofacitinib led to greater longitudinal improvement in physician global assessment and skin sclerosis in patients with #SSc.

View the full slide deck here:🔗https://t.co/t6XbHiqrLC

#SclerodermaForum https://t.co/M6QDq9lfMx

Alberto Giraldo @alb_giraldo

6 months ago

The combination of #tofacitinib and #leflunomide appears to be a promising novel therapeutic option for managing refractory #Takayasu arteritis, offering high remission rates, effective glucocorticoid (GC) sparing, reduced inflammation, favorable imaging outcomes, and good tolerability. This was evidenced in a pilot experience in 24 patients from the East China Takayasu Arteritis (ECTA) cohort (Zhongshan Hospital): ◦ Remission rates — High clinical efficacy was observed: - 87.5% (95% CI: 69.0%–95.7%) at 6 months - 79.2% (95% CI: 59.5%–90.8%) at 12 months ◦ Relapse rate: Low at 8.3% (95% CI: 2.3%–25.8%) over the 12-month follow-up. ◦ Glucocorticoid tapering — Significant and successful reduction in GC dose: - Baseline: 15.2 ± 12.9 mg/day - 6 months: 7.8 ± 4.5 mg/day (p = 0.02) - 12 months: 6.5 ± 4.5 mg/day (p = 0.001) ◦ Inflammatory markers — Notable improvement: - ESR decreased significantly from 36.3 ± 33.8 mm/h at baseline to 17.1 ± 17.6 mm/h at 12 months (p = 0.02). ◦ Vascular imaging — In the subset of 7 patients with follow-up MR angiography, stability or improvement was seen in 5/7 (71.4%). ◦ Safety — The regimen was well-tolerated, with only few and mild adverse events reported (no severe safety concerns highlighted). The regimen of tofacitinib combined with leflunomide might be a promising novel option in treating refractory Takayasu arteritis patients. However, larger, prospective studies would be needed to confirm these findings. *Chang S, Kong X, Ma L, et al. Therapeutic effect of tofacitinib combined with leflunomide for refractory Takayasu arteritis: pilot study. Semin Arthritis Rheum. 2026;152958. 🔗https://t.co/VTHTIYBpdP

$alb_giraldo's tweet photo. The combination of #tofacitinib and #leflunomide appears to be a promising novel therapeutic option for managing refractory #Takayasu arteritis, offering high remission rates, effective glucocorticoid (GC) sparing, reduced inflammation, favorable imaging outcomes, and good tolerability. This was evidenced in a pilot experience in 24 patients from the East China Takayasu Arteritis (ECTA) cohort (Zhongshan Hospital): ◦ Remission rates — High clinical efficacy was observed: - 87.5% (95% CI: 69.0%–95.7%) at 6 months - 79.2% (95% CI: 59.5%–90.8%) at 12 months ◦ Relapse rate: Low at 8.3% (95% CI: 2.3%–25.8%) over the 12-month follow-up. ◦ Glucocorticoid tapering — Significant and successful reduction in GC dose: - Baseline: 15.2 ± 12.9 mg/day - 6 months: 7.8 ± 4.5 mg/day (p = 0.02) - 12 months: 6.5 ± 4.5 mg/day (p = 0.001) ◦ Inflammatory markers — Notable improvement: - ESR decreased significantly from 36.3 ± 33.8 mm/h at baseline to 17.1 ± 17.6 mm/h at 12 months (p = 0.02). ◦ Vascular imaging — In the subset of 7 patients with follow-up MR angiography, stability or improvement was seen in 5/7 (71.4%). ◦ Safety — The regimen was well-tolerated, with only few and mild adverse events reported (no severe safety concerns highlighted). The regimen of tofacitinib combined with leflunomide might be a promising novel option in treating refractory Takayasu arteritis patients. However, larger, prospective studies would be needed to confirm these findings. *Chang S, Kong X, Ma L, et al. Therapeutic effect of tofacitinib combined with leflunomide for refractory Takayasu arteritis: pilot study. Semin Arthritis Rheum. 2026;152958. 🔗https://t.co/VTHTIYBpdP$

955

Jan Král

@KralJan

7 months ago

Acute Severe UC 🏥 remains a therapeutic emergency❗️ #Tofacitinib or #upadacitinib, does one outperform the other 🔬? First propensity-adjusted, multicenter comparison (n=111). 📘👉 https://t.co/ZRz8MEeVV1 #GITwitter #IBD #MedTwitter #MedEd @AGA_CGH @my_ueg @IBD_Sir @ibdseb

KralJan's tweet photo. Acute Severe UC 🏥 remains a therapeutic emergency❗️

#Tofacitinib or #upadacitinib, does one outperform the other 🔬?

First propensity-adjusted, multicenter comparison (n=111).

📘👉 https://t.co/ZRz8MEeVV1

#GITwitter #IBD #MedTwitter #MedEd @AGA_CGH @my_ueg @IBD_Sir @ibdseb https://t.co/0KYglrHMTm

Dermatology Times @DermTimesNow

7 months ago

📚 In a 10-patient series of omalizumab-refractory #CSU, #tofacitinib induced rapid remission in ~70% by week 8, with manageable safety. Responses were variable, with some relapse. https://t.co/Y13nAF7FxP #DermTwitter

214

Online Medicine Pharmacy @xeljanz5mg

7 months ago

Tofacitinib XR 11 mg An extended-release JAK inhibitor used in rheumatoid arthritis, psoriatic arthritis & ulcerative colitis. Generic Tofacitinib XR 11 mg WhatsApp: https://t.co/Z7PgWGxX2N #Tofacitinib #JAKInhibitor #GenericMedicine ⚠️ Disclaimer: Not medical advice.

xeljanz5mg's tweet photo. Tofacitinib XR 11 mg
An extended-release JAK inhibitor used in rheumatoid arthritis, psoriatic arthritis & ulcerative colitis.
Generic Tofacitinib XR 11 mg
WhatsApp: https://t.co/Z7PgWGxX2N
#Tofacitinib #JAKInhibitor #GenericMedicine
⚠️ Disclaimer: Not medical advice. https://t.co/Tf34n4EmXY

105

CCF(India) @CCF_IN

8 months ago

This latest review in @Intest_Res authored by Dr Ajit Sood, @dr_singh_gastro @vandana_midha @bhardwaj_arshia from @DMCH_Ludhiana, explores how #Tofacitinib is catalyzing a paradigm shift in the management of #UlcerativeColitis in India 🇮🇳 Read here : https://t.co/6qkhhGk0JN

CCF_IN's tweet photo. This latest review in @Intest_Res authored by Dr Ajit Sood, @dr_singh_gastro @vandana_midha @bhardwaj_arshia from @DMCH_Ludhiana, explores how #Tofacitinib is catalyzing a paradigm shift in the management of #UlcerativeColitis in India 🇮🇳

Read here : https://t.co/6qkhhGk0JN https://t.co/Wqee0l0pVP

444

CNBC-TV18

@CNBCTV18Live

10 months ago

#JustIn | #Biocon gets final US FDA nod for its ANDA for #Tofacitinib extended-release tablets

Rheumatology Quarterly @RheumQuarterly

10 months ago

#ACR25 #ACR2025 Lecture by Wilfong EM #tofacitinib in CTD-ILD? A new multicenter study (https://t.co/pHSOCNwqAY) showed that tofacitinib superior to calcineurin inhibitor in #ILD secondary to anti-MDA5+ #dermatomyositis @NeslihanGken7 @Janetbirdope @RheumNow @firatromatoloji

RheumQuarterly's tweet photo. #ACR25 #ACR2025

Lecture by Wilfong EM

#tofacitinib in CTD-ILD?

A new multicenter study (https://t.co/pHSOCNwqAY) showed that tofacitinib superior to calcineurin inhibitor in #ILD secondary to anti-MDA5+ #dermatomyositis
@NeslihanGken7 @Janetbirdope @RheumNow @firatromatoloji https://t.co/GWhK14eixL

854

Janet Pope @Janetbirdope

11 months ago

IgG4 - Rare but Rx Several studies #ACR25 @ACRheum were presented Outcome measures Rx #steroids #CD19 mAb #Inebilizumab 👍+RCT reduction of flares BTKi #Rilzabrutinib #Zanubrutinib #JAKi +RCT of #tofacitinib +steroids vs pred @ACRheum @RheumNow #ACR25 1163 LB02 0239 1172

Janetbirdope's tweet photo. IgG4 - Rare but Rx

Several studies #ACR25 @ACRheum were presented
Outcome measures

Rx
#steroids

#CD19 mAb #Inebilizumab
👍+RCT reduction of flares

BTKi
#Rilzabrutinib
#Zanubrutinib

#JAKi
+RCT of #tofacitinib +steroids vs pred

@ACRheum @RheumNow #ACR25
1163 LB02 0239 1172 https://t.co/xC3wgaN9bk

The Journal of Rheumatology @jrheum

about 1 year ago

Research Article Effective Treatment of Janus Kinase 1/3 Inhibitor in Blau Syndrome From a Multicenter Retrospective Study in Central China 📖 https://t.co/MK1v3MLB8T #Blausyndrome #Januskinaseinhibitors #tofacitinib

jrheum's tweet photo. Research Article

Effective Treatment of Janus Kinase 1/3 Inhibitor in Blau Syndrome From a Multicenter Retrospective Study in Central China

📖 https://t.co/MK1v3MLB8T

#Blausyndrome #Januskinaseinhibitors #tofacitinib https://t.co/2soBE0cEL4

587

Mucosal Immunology @MucosalImmunol

about 1 year ago

A Jak/Stat inhibitor, #Tofacitinib, can suppress IFNg production from ILCs and T cells, reducing tissue damage during ameliorates #Campylobacter https://t.co/0W7V5g1Irx

MucosalImmunol's tweet photo. A Jak/Stat inhibitor, #Tofacitinib, can suppress IFNg production from ILCs and T cells, reducing tissue damage during ameliorates #Campylobacter https://t.co/0W7V5g1Irx https://t.co/PGgbcBSKG2

972

Top Tweets for #TOFACITINIB

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users